Biocon is currently trading at Rs 379.35, up by 8.90 points or 2.40% from its previous closing of Rs 370.45 on the BSE.
The scrip opened at Rs 370.05 and has touched a high and low of Rs 386.80 and Rs 370.05 respectively. So far 89138 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 378.75 on 11-Nov-2013 and a 52 week low of Rs 255.00 on 04-Mar-2013.
Last one week high and low of the scrip stood at Rs 378.75 and Rs 351.50 respectively. The current market cap of the company is Rs 7588.00 crore.
The promoters holding in the company stood at 60.97% while Institutions and Non-Institutions held 18.06% and 20.97% respectively.
Biocon, Asia's leading biotechnology enterprise, is setting up Biocon Academy, a one-of-its-kind Centre of Excellence for Advanced Learning in Applied Bio-Sciences. Biocon Academy - an initiative by Biocon - aims to train and develop industry-ready talent for India's Biopharma sector and enable global competitiveness. The Academy will offer advanced learning in Biosciences that will provide the required proficiency for enhanced career prospects in biotechnology for engineering and science graduates. It will connect the industry and academia to maximize the opportunities for aspiring biotechnologists and to address the skill deficit of the sector.
The Academy's flagship program in collaboration with Keck Graduate Institute, California, the 'Biocon KGI Certificate Program in Biosciences,' is being opened for enrollments today, for the January 2014 session. The deadline for online application submission is December 6, 2013.
KGI is a premier American graduate institution, devoted solely to bioscience education and discovery. Their training and education programs have built a very strong capability in the US and it is through this partnership that we hope to emulate the success of KGI learning model in India.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.50 |
| Dr. Reddys Lab | 1220.50 |
| Cipla | 1232.75 |
| Zydus Lifesciences | 927.80 |
| Lupin | 2321.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: